Following the above treatment schedule, we found that multiple injections of 1 × 102 TCID50 of MMR resulted in significant tumor growth delay and extended survival compared to that in the control group (PBS) in Hepa 1-6 (tumor, p=0.003; survival, p<0.001; Figures 1C, D) and MC38 (tumor, p=0.02; survival, p=0.01; Figures 1E, F) models. Here, MRC1 is linked to neoplasm.